General Nutritional Status Clinical Trial
Official title:
Effects of Multivitamin, Multimineral and Phytonutrient Supplementation on Selected Nutrients Blood Level and Heart Health Risk Factors in Russian Population
| Verified date | August 2014 |
| Source | Access Business Group |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Russia: Ethics Committee |
| Study type | Interventional |
The objectives of this exploratory study are to (1) evaluate the effect of the multivitamin multimineral with phytonutrient product vs. placebo on heart health risk factors following twice-daily consumption for eight weeks; (2) To test the safety and tolerability of the multivitamin multimineral with phytonutrient product vs. placebo following twice-daily consumption for eight weeks.
| Status | Completed |
| Enrollment | 120 |
| Est. completion date | September 2013 |
| Est. primary completion date | July 2011 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Both |
| Age group | 40 Years to 70 Years |
| Eligibility |
Inclusion Criteria: - Generally healthy men and women aged from 40 to 70 years of age preferable smokers and who regularly consumes alcohol, and consuming fewer than 12 items found on the Recommended Foods Checklist (see below) per week. - Individual should be judged to be in good general health on the basis of an interview and abbreviated physical exam. - Individual understands the procedures and agrees to participate in the study. - Individual is able and willing to provide written informed consent and confidentiality agreement. Exclusion Criteria: - Use of dietary supplements within one week of Day 1. Supplements include any vitamins, minerals, and herbal products, including herbal drinks. - Presence of cardiovascular disease, hypercholesterolemia, cancer, diabetes mellitus, or any other chronic health condition identified from the findings of the interview. - Currently treated for uncontrolled hypertension or blood pressure greater > 140 mm Hg systolic or > 90 mm Hg diastolic during seated, resting measurement on two consecutive occasions during visit 1. - Therapeutic uses of coumadin, aspirin, or other medications that influence hemostasis within four weeks of Day 1. - Participation in another clinical trial within 30 days of enrollment into the study. - History or current abuse of drugs or alcohol, or intake > 4 alcoholic beverages per day. - Known hypersensitivity to study product or any ingredient in study product. - A change in hormone therapy, including oral contraceptives, within 4 weeks prior to screening, or unwilling to maintain current hormone therapy/oral contraceptive use throughout the course of the study. - Pregnant or lactating women, or women of child-bearing potential unwilling to use a medically approved form of birth control. - Any condition that the Principal Investigator believes may put the subject at undue risk. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention
| Country | Name | City | State |
|---|---|---|---|
| Russian Federation | Russian Institute of Nutrition | Moscow |
| Lead Sponsor | Collaborator |
|---|---|
| Access Business Group | Russian Institute of Nutrition |
Russian Federation,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Other | Change of anthropomorphic evaluation markers by measuring height, weight, body mass index (BMI, kg/m2), and waist-to-hip ratio at baseline and Day 56 | Baseline and Day 56 | No | |
| Other | Evaluation of general health status, lifestyle and dietary behavior | dietary questionnaire was used. | Baseline | No |
| Primary | Change of heart risk factors by measuring homocysteine, C reactive protein (CRP), oxidized low-density lipoprotein (Ox-LDL) and lipid profile at baseline and Day 56 | Baseline, Day 56 | No | |
| Primary | Change of nutrient status by measuring b-carotene, a- and r-tocopherol, vitamin C, folic acid, B6, B12, zinc, selenium, polyphenols at baseline, Day 28 and Day 56 | Baseline, Day 28 and Day 56 | No | |
| Secondary | Change of potential heart health risk factors by measuring gamma-glutamyl transferase (GGT) and uric acid | Baseline and Day 56 | No |